Stevard LLC’s Sarepta Therapeutics SRPT Stock Holding History

Stevard LLC’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,531	Closed	-$245K	–	177
2020 Q2	$245K	Buy	+1,531	New	+$208K	0.13%	118

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stevard LLC's SRPT Position: Q3 2020 in Review

Stevard LLC sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 1,531 shares — an estimated $245K sold.

Stevard LLC first reported a position in SRPT in Q2 2020 and held it in 1 quarter. The position peaked at $245K in Q2 2020. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

Stevard LLC reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
Stevard LLC sold 1,531 Sarepta Therapeutics shares in Q3 2020, an estimated $245K.
Stevard LLC first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 1 quarter.
Stevard LLC's Sarepta Therapeutics position peaked at $245K in Q2 2020.
403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Stevard LLC's 13F filing for Q3 2020, filed 12 Nov 2020.